Category: HEALTHCARE & MEDICINE
First-of-its-Kind Leukemia Drug Blincyto Bags another FDA Approval
Amgen’s immunotherapy Blincyto (blinatumomab) received USFDA approval for the treatment of children and adults with B-cell precursor acute lymphoblastic leukemia ...
New Potential Immuno-Oncology Drug for Blood Cancer Received Orphan Drug Status
Chinese biotech, Maxinovel Pharma’s immuno-oncology drug candidate- MAX-40279 received Orphan Drug designation from the US FDA for the treatment of ...
Ovarian Cancer Drug Zejula Shows Historical Results in Combination for Hard-to-Treat Cancer
KEY POINTS Zejula plus Keytruda improved the clinical benefits significantly in difficult-to-treat ovarian cancer patients than any one of them ...
FDA Approves New Therapy Trogarzo for Difficult-to-Treat Multidrug Resistant HIV
KEY POINTS FDA approves humanized monoclonal antibody, Trogarzo (ibalizumab-ulyk) to treat patients with multidrug-resistant HIV-1 infection. First HIV therapy in ...
AstraZeneca Spinout Viela Bio Fetches $250 M, Pushes Pipeline Autoimmune Drugs in Clinical Study
AstraZeneca subsidiary, MedImmune has spun out a new inflammation- and autoimmunity-focused biotech, Viela Bio with six molecules from MedImmune. The ...
Merck’s New Class of Drugs Shows Potential against Resistant Cancers
KEY POINTS ERK inhibitors are the new class of drugs in development for resistant cancers Merck’s ERK inhibitor, MK-8353 in ...
8 Most Promising Vaccines Under Development (2018)
KEY POINTS Here are some of the most promising vaccines on their way in 2018. Vaccines protect against a large ...
FDA Approves Glatopa, Generic Version of Teva’s Top-Selling Multiple Sclerosis Drug Copaxone
US FDA approved Glatopa®, generic version of Teva’s Copaxone developed by Sandoz (Novartis’ biosimilar division) in collaboration with Momenta Pharma. ...
FDA Approves Vertex Pharma’s Third Cystic Fibrosis Drug Symdeco
Vertex Pharma’s third cystic fibrosis drug, Symdeco™ received the US FDA approval for treating the underlying causes of cystic fibrosis ...
Pfizer’s Lorlatinib Gets FDA Priority Review Status to Treat ALK-Positive Lung Cancer
KEY POINTS Lorlatinib is a next-generation ALK/ROS1 tyrosine kinase inhibitor. Last year, lorlatinib had received Breakthrough Therapy designation from the ...